Article
Lilly :Mounjaro Shows 2.2% A1C Drop In Phase 3 Trial For Children & Adolescents With Type 2 Diabetes
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from SURPASS-PEDS, the first Phase 3 trial evaluating the safety and efficacy of Mounjaro (tirzepatide)—a GIP/GLP-1 dual receptor agonist—in children and adolescents (ages 10 to under 18) with type 2 diabetes inadequa
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
Sep 18, 2025 · 1:36 am
Article ID
53143854169227590931
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This